therapeut
medicin
today
includ
vast
number
procedur
involv
use
biomateri
transplant
therapeut
cell
cell
cluster
well
solid
organ
treatment
modal
obvious
great
benefit
patient
also
present
great
challeng
innat
immun
system
sinc
involv
direct
exposur
nonbiolog
materi
cell
nonhematolog
origin
well
endotheli
cell
damag
ischemiaperfus
solid
organ
protein
cell
blood
result
exposur
may
inappropri
activ
complement
contactkallikrein
system
produc
mediat
capabl
trigger
platelet
pmn
monocyt
ultim
result
thrombot
inflammatori
ie
thromboinflammatori
respons
treatment
modal
concept
review
give
overview
mechan
recognit
within
innat
immun
system
aim
identifi
suitabl
point
intervent
final
discuss
emerg
promis
techniqu
surfac
modif
biomateri
cell
specif
inhibitor
order
diminish
thromboinflamm
improv
clinic
outcom
inappropri
uncontrol
activ
cascad
system
blood
drive
forc
advers
inflammatori
thrombot
thromboinflammatori
reaction
therapeut
medicin
procedur
involv
biomateri
drug
deliveri
devic
transplant
cell
cell
cluster
solid
organ
therapi
often
associ
advers
reaction
involv
innat
immun
system
physiolog
condit
import
particip
immedi
defens
alienforeign
substanc
microorgan
similar
manner
reactiv
surfac
medic
equip
well
surfac
transplant
cell
solid
organ
trigger
innat
immun
respons
orchestr
thromboticinflammatori
reaction
ultim
result
poor
outcom
therapi
andor
damag
host
conceptu
review
describ
basic
mechan
cascad
system
activ
variou
therapeut
condit
highlight
strategi
dampen
advers
reaction
focu
number
emerg
techniqu
link
specif
inhibitor
direct
key
compon
variou
cascad
system
directli
surfac
biomateri
cellular
surfac
therebi
provid
local
inhibit
addit
briefli
mention
two
clinic
avail
inhibitor
system
administr
thromboinflamm
complex
process
involv
activ
humor
innat
immun
system
consist
cascad
system
blood
ie
complement
contact
activationcoagul
fibrinolyt
system
initi
trigger
induc
activ
cellular
system
blood
platelet
subpopul
leukocyt
within
innat
branch
immun
system
endotheli
cell
line
blood
vessel
multipl
point
interact
crosstalk
humor
cellular
portion
innat
immun
system
mean
moder
initi
activ
signal
rapidli
dramat
amplifi
process
trigger
medic
treatment
procedur
treatment
biomateri
drug
deliveri
devic
transplant
cell
cell
cluster
solid
organ
end
result
may
thromboticinflammatori
reaction
diminish
efficaci
treatment
case
transplant
induc
graft
impair
reject
process
detriment
patient
undergo
treatment
review
complement
play
import
role
bodi
identifi
remov
intrud
pathogen
also
clear
apoptot
necrot
autolog
cell
antigenantibodi
complex
order
carri
function
use
capac
detect
differ
healthi
autolog
cell
self
damag
apoptot
autolog
cell
alter
self
well
pathogen
microorgan
nonself
identifi
nonself
alteredself
structur
trigger
cascad
reaction
ultim
lead
destruct
remov
unwant
cell
pathogen
either
phagocytosi
direct
lysi
complement
system
compris
protein
present
fluid
phase
plasma
bound
autolog
cell
function
receptor
regul
activ
complement
occur
via
three
differ
pathway
classic
pathway
cp
lectin
pathway
lp
altern
pathway
ap
three
pathway
lead
assembl
cplp
ap
cleav
anaphylatoxin
opsonin
everi
gener
moieti
potenti
nucleu
new
ap
complex
henc
ap
provid
potent
amplif
loop
complement
activ
regardless
natur
initi
trigger
cp
initi
moieti
complex
also
consist
proenzym
bind
targetbound
antibodi
pentraxin
dna
neg
charg
substanc
lp
initi
recognit
molecul
mannanbind
lectin
mbl
complex
mblassoci
serin
proteas
masp
bind
carbohydr
case
bind
target
surfac
induc
activ
enzymat
compound
mediat
proteolyt
activ
lead
format
cplp
convertas
activ
ap
facilit
properdin
bind
also
via
socal
tickov
mechan
wherebi
intern
thiol
ester
disrupt
h
form
acquir
properti
form
initi
ap
convertas
h
bb
fluid
phase
addit
associ
either
convertas
alter
substrat
specif
result
switch
cleavag
anaphylatoxin
cleavag
first
step
termin
pathway
ultim
form
membran
attack
complex
mac
consist
multipl
copi
mac
promot
cell
lysi
via
insert
lipid
bilay
cell
membran
termin
complex
also
present
complex
vitronectin
solubl
abort
form
term
import
effector
function
complement
addit
direct
cell
lysi
mac
includ
recruit
activ
pmn
monocyt
anaphylotoxin
potent
phagocytosi
target
particl
facilit
interact
targetbound
opsonin
fragment
complement
receptor
crig
upregul
phagocyt
cell
respons
anaphylatoxin
vivo
complement
system
control
sever
solubl
membranebound
regul
protect
cell
damag
caus
autolog
complement
regul
member
regul
complement
activ
rca
superfamili
predomin
regul
convertas
plasma
protein
factor
h
regul
ap
protein
regul
cp
lp
membranebound
protein
membran
cofactor
protein
mcp
decay
acceler
factor
daf
belong
famili
fluidphas
regul
recruit
host
cell
bind
cellsurfac
glyocosaminoglycan
addit
cellbound
well
fluidphas
vitronectin
clusterin
prevent
format
lytic
mac
complex
host
cell
regul
complement
activ
autolog
cell
shown
fig
protein
contact
system
factor
f
xii
fxi
prekallikrein
pk
circul
zymogen
high
molecular
weight
kininogen
hk
function
cofactor
cleavag
fxi
pk
bind
fxii
materi
surfac
induc
conform
chang
fxii
protein
induc
nonproteolyt
autoactiv
molecul
activ
enzym
form
cleav
solubl
fxii
enzymat
activ
fxiia
initi
two
differ
pathway
one
substrat
pk
becom
cleav
kallikrein
kk
hk
cofactor
gener
kk
activ
solubl
fxii
turn
gener
kk
provid
ing
effect
amplif
loop
addit
kk
also
cleav
hk
releas
bradykinin
nonapeptid
potent
proinflammatori
vasoact
properti
substrat
fxi
cleav
fxia
hk
cofactor
therebi
initi
intrins
pathway
coagul
ultim
end
activ
thrombin
prothrombin
subsequ
fibrin
format
fibrin
clot
abl
promot
activ
fxii
establish
anoth
amplif
loop
relat
contact
system
activ
gener
contact
activ
proteas
fxiia
fxia
kk
subsequ
regul
serin
proteas
inhibitor
serpin
inhibitor
antithrombin
ubiquit
present
plasma
predomin
inhibitor
contact
system
proteas
activ
initi
neg
charg
surfac
glass
kaolin
contrast
situat
contact
system
activ
follow
platelet
activ
trigger
preform
fibrin
clot
proteaseat
complex
almost
complex
detect
addit
activ
fibrin
clot
platelet
contact
system
activ
also
demonstr
occur
upon
interact
activ
endotheli
cell
current
understand
activ
regul
contact
activ
pathway
present
fig
apart
tradit
role
platelet
mediat
hemostasi
evid
emerg
indic
platelet
activ
thrombot
event
close
associ
activ
complement
contactkallikrein
system
lead
inflamm
platelet
act
innat
immun
cell
chondroitin
sulfat
csa
releas
platelet
activ
potent
mediat
crosstalk
platelet
complement
system
csa
activ
complement
fluid
phase
gener
anaphylatoxin
mediat
leukocyt
activ
initi
complement
activ
seem
occur
platelet
surfac
form
h
bound
surfac
activ
platelet
addit
sever
complement
compon
detect
surfac
activ
platelet
lack
complement
activ
despit
abund
bound
complement
protein
consist
strong
express
membranebound
complement
regul
high
densiti
plasmaderiv
complement
regul
factor
h
vitronectin
partial
bound
via
csa
platelet
surfac
plateletbound
h
act
ligand
leukocyt
therebi
serv
import
ligand
tether
activ
platelet
pmn
becom
activ
interact
activ
platelet
clot
regul
masp
previous
report
involv
coagul
cleav
prothrombin
thrombin
number
thrombinlik
effect
cleav
fibrinogen
fxiii
hk
thrombinactivat
fibrinolysi
inhibitor
tafi
thu
abl
mediat
format
insolubl
fibrin
recent
report
becom
activ
interact
preform
fibrin
produc
use
purifi
fibrinogen
thrombin
without
involv
platelet
henc
interact
fibrin
masp
may
repres
crossroad
complement
coagul
system
well
anoth
amplif
mechan
analog
fxii
fibrin
mention
section
activ
fibrin
inactiv
exclus
without
presenc
heparin
cofactor
physiolog
relev
find
underscor
observ
complex
detect
plasma
sampl
patient
differ
thromboinflammationrel
diagnos
mention
section
contact
system
activ
link
platelet
activ
gener
proteas
fxiia
fxia
kk
case
preferenti
regul
vitro
vivo
activ
platelet
bind
high
amount
four
contact
activ
protein
fxii
fxi
pk
hk
enzymat
activ
three
proteas
found
surfac
activ
nonactiv
platelet
contact
activ
neg
charg
surfac
misfold
protein
surfac
fxii
adsorb
neg
charg
surfac
misfold
protein
surfac
undergo
conform
chang
gener
surfaceadsorb
subsequ
liber
two
pathway
initi
left
activ
fxi
subsequ
lead
coagul
activ
right
activ
kallikrein
pathway
induc
inflammatori
respons
fluid
phaseactiv
compon
fxia
kk
inhibit
either
anaphylatoxin
caus
smooth
muscl
contract
histamin
releas
mast
cell
enhanc
vascular
permeabl
addit
recruit
pmn
monocyt
chemotaxi
activ
increas
express
activ
review
also
demonstr
upregul
tissu
factor
tf
monocyt
pmn
cytolyt
inact
induc
tf
express
human
endotheli
cell
furthermor
capabl
activ
platelet
indirectli
via
immun
complex
leukocyt
endotheli
cell
activ
bradykinin
produc
contact
system
thrombin
major
end
product
contact
activationcoagul
system
potent
platelet
activ
upon
contact
blood
foreign
structur
surfac
nonbiolog
bio
materi
liposom
drug
deliveri
nonhematolog
cell
alteredself
structur
endotheli
line
solid
organ
identifi
alien
recognit
molecul
intravascular
innat
immun
system
trigger
respons
mechan
direct
initi
agent
mechan
activ
subsequ
advers
advent
differ
thu
need
intervent
divers
point
aim
review
articl
describ
gener
process
lead
thromboinflamm
subsequ
event
may
ultim
lead
treatment
failur
andor
host
damag
multifactor
depend
exampl
composit
structur
biomateri
puriti
cell
use
cell
treatment
qualiti
organ
transplant
determin
factor
may
age
condit
donor
time
ischemia
other
importantli
underli
diseas
condit
patient
receiv
treatment
artifici
bio
materi
come
contact
blood
first
event
occur
instantan
protein
adsorpt
onto
materi
surfac
observ
within
first
second
plasma
protein
form
monolay
materi
surfac
composit
protein
layer
amount
individu
protein
deposit
mainli
affect
materi
inher
chemic
physic
properti
among
plasma
protein
igg
preferenti
bind
materi
surfac
alter
conform
therebi
trigger
cp
ap
activ
respect
complement
system
activ
coval
bind
protein
film
surfac
activ
amplif
loop
gener
fragment
fragment
ultim
conceal
initi
protein
layer
enhanc
releas
well
fluid
phase
anaphylatoxin
potent
chemoattract
bind
pmn
monocyt
recruit
biomateri
site
activ
leukocyt
recogn
surfacebound
fragment
via
ligand
initi
opson
cytokin
releas
thrombi
biomateri
surfac
form
plateletmedi
reaction
coagul
activ
plasma
protein
fibrinogen
fibronectin
vitronectin
potent
mediat
platelet
adhes
prone
bind
materi
surfac
minut
amount
fibrinogen
suffici
induc
primari
platelet
activ
via
integrin
interact
addit
fxii
adsorb
onto
materi
surfac
automat
activ
contact
system
pathway
coagul
cascad
gener
thrombin
turn
intens
activ
platelet
furthermor
igg
igm
human
serum
albumin
hsa
demonstr
potenti
activ
fxii
lead
contact
pathway
activ
gener
biomateri
surfac
lack
complement
coagul
regul
therefor
cascad
system
activ
spin
control
result
accumul
anaphylatoxin
activ
immun
cell
gener
thrombi
sequenc
event
summar
fig
recent
studi
protein
adsorpt
plasma
well
complement
contact
system
activ
cytokin
gener
whole
blood
induc
model
biomateri
six
novel
wellcharacter
artifici
polym
three
refer
polym
brief
polym
ground
particl
incub
edtaplasma
monitor
adsorpt
select
protein
plasma
contain
lepirudin
specif
thrombin
inhibitor
evalu
contact
system
activ
monitor
format
complex
gener
proteas
fxiia
fxia
kk
serpin
cascad
system
activ
biomateri
surfac
plasma
protein
quickli
adsorb
materi
surfac
make
contact
blood
top
plasma
protein
film
complement
left
coagul
right
trigger
amplifi
gener
either
anaphylatoxin
recruit
leukocyt
induc
inflammatori
respons
thrombin
recruit
platelet
catalyz
clot
format
lepirudinanticoagul
whole
blood
determin
complement
activ
monitor
gener
cytokin
gener
releas
main
find
ratio
repres
regul
complement
system
ratio
repres
regul
contact
activ
system
adsorb
edtaplasma
neg
correl
neg
correl
found
contact
activationserpin
complex
impli
surfac
preferenti
activ
one
system
strong
correl
found
ratio
posit
ratio
neg
b
gener
cytokin
mainli
proinflammatori
includ
correl
gener
cytokin
complement
activ
product
neglig
corrobor
poor
predict
valu
biocompat
marker
gener
conclus
work
artifici
surfac
contact
blood
preferenti
activ
complement
system
contact
system
ratio
andor
adsorb
edtaplasma
shown
use
surrog
marker
cytokin
releas
inflammatori
respons
materi
intend
blood
contact
sever
extracorpor
circul
devic
design
use
cardiopulmonari
bypass
cpb
extracorpor
membran
oxygen
ecmo
hemodialysi
hemofiltr
plasmapheresi
artifici
materi
involv
often
expos
fresh
blood
tissu
fluid
sinc
surfac
free
energi
materi
high
protein
adsorpt
usual
occur
onto
materi
surfac
surfac
come
contact
blood
tissu
fluid
protein
adsorpt
evok
sequenc
event
involv
inflammatori
reaction
activ
complement
coagul
system
induc
immunocompet
cell
recogn
materi
foreign
bodi
adher
surfac
artifici
materi
sequenti
event
result
seriou
thromboinflammatori
incompat
reaction
materi
implant
exampl
life
expect
significantli
decreas
urem
patient
result
arteriosclerosi
partli
due
chronic
wholebodi
inflamm
trigger
hemodialysi
higher
risk
myocardi
infarct
hemodialysi
patient
healthi
individu
addit
cpb
ecmo
procedur
increas
past
decad
patient
vascular
bypass
surgeri
begun
suffer
longlast
infect
affect
lung
eg
swine
influenza
sever
acut
respiratori
syndrom
sar
cpb
ecmo
procedur
usual
associ
system
inflammatori
respons
syndrom
sir
contact
blood
materi
surfac
evok
cellular
humor
defens
reaction
even
vascular
stent
small
implant
induc
fibrosi
restenosi
thrombosi
expos
bloodstream
cardiac
aid
pump
trigger
thrombot
reaction
lead
emboli
thu
thromboinflammatori
reaction
induc
implant
site
lead
deleteri
effect
also
see
similar
inflammatori
reaction
simultan
activ
innat
immun
thrombot
cascad
therapeut
cell
islet
langerhan
mesenchym
stemstrom
cell
msc
hepatocyt
infus
human
bodi
administr
cell
usual
associ
larg
loss
transplant
cell
result
thromboinflamm
also
term
instant
bloodmedi
inflammatori
reaction
ibmir
cell
surfac
expos
host
blood
innat
immun
system
trigger
thromboinflamm
occur
cell
surfac
due
express
tf
rapid
bind
platelet
infil
fig
complement
dysregul
damag
ischem
allogen
cell
surfac
innat
immun
recognit
molecul
mbl
ficolin
collectin
recogn
alter
self
structur
cell
natur
igm
may
also
bind
initi
complement
activ
complement
regul
present
suffici
densiti
cell
surfac
complement
mediat
attack
may
lead
cell
death
apoptosi
tration
leukocyt
clot
result
earli
loss
transplant
cell
result
loss
transplant
cell
addit
tf
collagen
also
involv
activ
thromboinflamm
exampl
msc
system
infus
patient
reduct
platelet
count
signific
increas
thrombinantithrombin
tat
ie
marker
thrombin
activ
elev
level
detect
within
h
also
report
case
clinic
hepatocyt
transplant
increas
tat
level
reduct
platelet
concentr
found
within
hour
transplant
conclus
transplant
cell
may
expect
destroy
thromboinflammatori
reaction
immedi
infus
correspond
reaction
wholeorgan
transplant
ischemiareperfus
injuri
iri
xenogenicallogen
antibodymedi
reject
major
mediat
cell
damag
transplant
also
trigger
complement
activ
thrombot
reactioninduc
thromboinflamm
iri
occur
upon
reestablish
blood
suppli
cell
tissu
organ
expos
prolong
imbal
oxygennutri
suppli
demand
critic
reaction
inevit
event
organ
transplant
iri
also
occur
wide
rang
clinic
relev
situat
brain
death
sepsi
cardiac
surgeri
well
revascular
myocardi
infarct
stroke
iri
complex
pathophysiolog
process
involv
cascad
advers
event
includ
hypoxia
atp
exhaust
mitochondri
damag
increas
product
reactiv
oxygen
speci
ionic
imbal
ultim
lead
structur
lesion
endotheli
cell
initi
activ
innat
immun
subsequ
adapt
immun
endotheli
cell
surfac
normal
cover
neg
charg
glycocalyx
consist
complex
network
proteoglycan
glycosaminoglycan
glycoprotein
well
number
antiinflammatori
anticoagul
protein
ensur
microvascular
homeostasi
prevent
thromboinflamm
moreov
thick
shield
engulf
adhes
molecul
prevent
recruit
leukocyt
platelet
endotheli
surfac
iri
vascular
protect
barrier
vascular
glycocalyx
lost
result
decreas
adenyl
cyclas
activ
increas
vascular
permeabl
hypox
condit
tf
togeth
proinflammatori
cytokin
chemokin
express
endotheli
stromal
cell
surfac
also
deposit
complement
compon
onto
cell
surfac
reaction
lead
trigger
local
inflamm
bind
platelet
infiltr
leukocyt
particularli
pmn
respons
lead
loss
integr
endotheli
cell
ultim
caus
vascular
damag
exposur
circul
fresh
blood
hypox
cell
also
attack
innat
immun
system
recogn
cell
alter
self
structur
attack
aggrav
condit
final
lead
cell
death
apoptosi
recognit
molecul
process
fxii
mbl
ficolin
also
crp
natur
antibodi
igm
isotyp
like
also
involv
also
implic
reaction
fig
develop
fluidphas
complement
inhibitor
rapidli
grow
field
number
promis
candid
molecul
pipelin
recent
survey
field
found
present
two
complement
inhibitor
avail
clinic
behrinet
plasmaderiv
ruconest
recombin
human
monoclon
antibodi
eculizumab
soliri
specif
complement
inhibitor
also
regul
proteas
gener
contact
system
section
properti
like
reason
success
treatment
hereditari
angioedema
major
indic
howev
inh
also
show
promis
result
sever
diseas
model
includ
transplant
contrast
eculizumab
complementspecif
inhibit
cleavag
convertas
therebi
prevent
gener
mac
complex
main
indic
paroxysm
nocturn
hemoglobinuria
pnh
atyp
hemolyt
urem
syndrom
ahu
also
shown
produc
prompt
revers
sever
complement
activ
patient
undergo
intent
aboincompat
pancrea
kidney
transplant
immobil
adpdegrad
enzym
surfac
materi
cell
effect
regul
coagul
system
platelet
activ
multistep
process
begin
involv
adhes
aggreg
contract
secret
releas
adp
essenti
recruit
aggreg
platelet
therefor
obviou
target
achiev
platelet
inhibit
nilsson
et
al
report
adpdegrad
enzym
apyras
immobil
onto
substrat
surfac
inhibit
platelet
activ
plateletdepend
activ
coagul
system
idea
come
ec
enzym
express
human
endotheli
cell
adpdegrad
activ
similar
apyras
order
regul
platelet
activ
vascular
adp
continu
degrad
homeostat
condit
fact
immobil
apyras
attenu
activ
platelet
coagul
system
ideal
approach
would
mimic
properti
endotheli
cell
line
nativ
vascular
wall
heparan
sulfat
heparinlik
molecul
express
endotheli
cell
surfac
play
import
role
regul
coagul
well
complement
platelet
activ
therefor
immobil
heparin
ration
approach
regul
thromboinflamm
immobil
heparin
onto
stent
prevent
platelet
activ
also
coagul
activ
also
possibl
immobil
apyras
heparin
cell
surfac
amphiphil
polym
poli
ethylen
glycol
conjug
phospholipid
peglipid
deriv
fig
peglipid
interact
lipid
bilay
cell
membran
hydrophob
interact
without
caus
either
cytotox
volum
increas
end
peg
deriv
face
fluid
phase
function
allow
bind
peptid
protein
oligonucleotid
apyras
immobil
cell
surfac
porcin
aortic
endotheli
cell
paec
shown
prevent
coagul
activ
well
platelet
activ
human
whole
blood
addit
heparin
conjug
immobil
onto
cell
surfac
use
peptid
highaffin
toward
heparin
cell
surfac
modifi
heparinbind
peptideconjug
peglipid
heparin
conjug
bind
therebi
demonstr
nativ
conform
human
msc
hepatocyt
modifi
heparin
conjug
thromboinflamm
regul
human
whole
blood
regard
regul
complement
system
util
fluidphas
rca
factor
h
effect
local
regul
surfac
materi
cell
sever
studi
indic
complement
activ
materi
surfac
initi
cp
concept
exploit
complementregulatori
effect
foreign
surfac
report
engberg
et
al
use
streptococc
proteinderiv
peptid
specif
recruit
human
substrat
surfac
therebi
reduc
complement
activ
via
cp
suggest
rcabind
peptid
may
promis
regul
complement
activ
surfac
ap
convertas
major
import
abil
amplifi
reaction
surfac
therefor
critic
regul
ap
convertas
order
avoid
complement
attack
mobil
factor
h
surfac
materi
cell
offer
possibl
approach
regul
complement
system
ap
explor
use
purifi
coval
immobil
factor
h
regul
complement
activ
anoth
approach
use
factor
hbind
peptid
specif
recruit
factor
h
plasma
host
variou
peptid
high
affin
variou
domain
human
factor
h
creat
one
peptid
recruit
factor
h
without
interf
regulatori
function
sinc
bound
region
regul
interact
convertas
immobil
onto
materi
factor
h
specif
recruit
host
blood
onto
surfac
therebi
mimick
host
surfac
protect
host
cell
attack
complement
moreov
also
possibl
coimmobil
apyras
autoregulatori
thromboinflamm
surfac
modif
apyras
appli
substrat
artifici
materi
cell
platelet
intim
involv
incompat
process
occur
foreign
surfac
directli
activ
surfac
platelet
close
connect
coagul
cascad
also
interact
leukocyt
trigger
activ
complement
therebi
act
import
hub
mediat
crosstalk
compon
therefor
critic
regul
coagulationplatelet
activ
complement
activ
use
cellsurfac
modif
techniqu
employ
peglipid
deriv
possibl
coimmobil
apyras
onto
cell
surfac
paec
expos
human
whole
blood
factor
h
specif
recruit
modifi
surfac
inhibit
complement
attack
addit
activ
platelet
coagul
effici
attenu
result
adp
degrad
thu
inhibit
thromboinflamm
multicompon
approach
creat
hybrid
surfac
potenti
greatli
reduc
incompat
reaction
involv
biomateri
transplant
coat
materi
surfac
cell
synthet
polym
peg
poli
phosphoryl
cholin
pmpc
also
effect
improv
blood
compat
biocompat
fig
coat
peg
pmpc
prevent
protein
adsorpt
plasma
protein
materi
cell
surfac
expos
blood
tissu
fluid
thu
coat
surfac
reduc
risk
incompat
reaction
sinc
mpc
polym
effect
suppress
protein
adsorpt
platelet
adhes
platelet
activ
materi
coat
mpc
polym
use
variou
biomed
applic
bloodcontact
cardiovascular
devic
thromboinflamm
major
obstacl
modern
therapeut
medicin
term
thromboinflamm
refer
advers
inflammatori
thrombot
crosstalkreact
initi
propag
differ
constitu
innant
immun
system
ultim
may
result
thrombosi
andor
chronic
inflamm
thromboinflamm
trigger
biomateri
lack
physiolog
inhibitor
present
autolog
cell
well
therapeut
cell
contact
blood
uncontrol
advers
reaction
may
caus
damag
implant
graft
andor
recipi
therefor
control
thromboinflamm
major
hurdl
overcom
order
improv
result
number
treatment
use
biomateri
transplant
cell
andor
whole
organ
target
surfac
biomateri
surfac
therapeut
cell
solid
organ
specif
inhibitor
promis
approach
decreas
thromboinflamm
therebi
improv
clinic
outcom
author
declar
conflict
interest
